[The role of radiation therapy in the management of non-Hodgkin's lymphoma].
For patients with stage I-II malignant lymphoma with low-grade malignancy, five-year survival rates after radiation therapy are 75-100%. For patients with intermediate malignancy, five-year survival rates after radiation therapy alone are 70-100% for patients with pathological stage I-II and 45-75% for clinical stage I-II. Radiation dose to the tumor at least 40 Gy was required to produce consistent local control. Initial use of chemotherapy with radiation therapy is indicated to improve relapse-free survival rate for patients with clinical stage I-II, as well as pathological stage I-II.
Masaki
N
N
Dept. of Radiology, Osaka Univ. Med. School.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy; D011879:Radiotherapy Dosage; D012074:Remission Induction